JLS Fund
JLS Fund is a New York-based venture capital firm founded in 2019 investing at the intersection of psychedelics and neuroscience. It serves accredited investors, family offices, and syndicates, deploying capital into early-stage biotech and psychedelic-medicine companies and earning returns through management fees and carried interest.
- Company typePrivate
- Founded2019
- HeadquartersNew York, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What JLS Fund does
JLS Fund is a New York-based venture capital firm founded in 2019 that invests at the intersection of neuroscience, psychedelic medicine, and related technology. The firm serves accredited investors, family offices, and investment syndicates as limited partners, generating returns through management fees on committed capital and carried interest from portfolio exits. With 1-10 employees and headquarters at 40 Sutton Place, New York, JLS Fund operates as a high-conviction boutique vehicle rather than a diversified generalist fund, deploying capital thematically into early-stage neuromedicine companies.
JLS Fund's portfolio spans more than 16 companies across the psychedelic-medicine and neuromedicine value chain. Core positions include Enthea (ketamine-assisted therapy access), ProNovo Therapeutics (precision therapeutics for Major Depressive Disorder and Schizophrenia), Psilera Bioscience (psychoactive natural-product neurology), Tripp (psychedelic wellness platform), Immunis Biomedical (multi-active biologics for age-related disease and immune dysregulation), and Gilgamesh Pharmaceuticals (clinical-stage psychiatric therapeutics). The September 2025 billion-dollar commitment from AbbVie to portfolio company Gilgamesh represents a material validation and potential liquidity event for the fund. The portfolio also includes earlier- or smaller-stake bets such as Aivita, Ceretype, FireflyVR, Fluence, Hemispheric, Homecoming, Ksana, Lief, Naiture.ai, and PsyThx. Business Insider named JLS Fund a top psychedelics VC in 2022.
The fund's go-to-market combines direct relationship-driven LP outreach with an online accredited-investor qualification survey, supplemented by an active thought-leadership platform: a weekly Substack newsletter ("This Week in Psychedelics and Neuroscience"), the "The Last Alchemist" podcast hosted by advisor Leonard Pickard, a YouTube channel, and speaking engagements at industry conferences including MAPS Psychedelic Science, Benzinga Psychedelic Capital, and Wonderland Miami. Leadership comprises Managing Partners Lindsay Hoover and Simeon Schnapper, Partner for Investor Relations Jeffrey Siegel, and Principal Brendan Hussey, supported by an advisory board spanning psychedelic research, drug policy, and media (Leonard Pickard, Ethan Nadelmann, Nick Gillespie, Walter Greenleaf, Gul Dolen, Mark Losh, David Hirsch, Andrew Tatarsky). The firm claims "top decile" performance and does not publicly disclose fund size, terms, or returns.
JLS Fund firmographics
Firmographics- Name
- JLS Fund
- Legal name
- JLS Fund
- Website
- https://jls.fund
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- JLS Fund is a New York-based venture capital firm founded in 2019 investing at the intersection of psychedelics and neuroscience. It serves accredited investors, family offices, and syndicates, deploying capital into early-stage biotech and psychedelic-medicine companies and earning returns through management fees and carried interest.
- Ownership category
- akta.pro rank
JLS Fund industry classification
Industry- Product category
- Venture Capital Fund
- NAICS
- Portfolio Management and Investment Advice (523940)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Early-Stage Venture Capital (Series A/B) (FSANAAAB)
- akta.pro secondary industry
- Healthcare Access & Life Sciences Impact Funds (FSANAJAI)
Keywords
Where JLS Fund is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
JLS Fund business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Others
Revenue model
- Venture Capital Fund Management: JLS Fund generates returns through equity investments in early-stage biotech and neuroscience companies. Revenue is derived from management fees on committed capital and carried interest (performance fees) when portfolio companies achieve exits through acquisitions or IPOs.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels7 records
JLS Fund product offering
Product offeringCore offering
JLS Fund is a venture capital fund that finances and helps build companies translating breakthroughs in neuroscience, technology, and data into patient outcomes and value for strategic acquirers. The fund focuses on precision neuromedicine, particularly in the psychedelic medicine sector, deploying capital into early-stage biotech, neuroscience, and digital health companies. Investors gain exposure through management fees on committed capital and carried interest on portfolio exits.
Product overview
JLS Fund is a venture capital fund (not a product company) that finances and helps build companies translating breakthroughs in neuroscience, technology, and data into patient outcomes. The fund operates as a single unified investment offering, deploying capital into a portfolio of neuroscience and psychedelic medicine companies including Enthea (ketamine therapy), ProNovo Therapeutics (neuropsychiatric disorders), Psilera Bioscience (neurological products), Tripp (wellness platform), Immunis Biomedical (age-related diseases), and Gilgamesh Pharmaceuticals (psychiatric disease treatments).
Differentiator
Problem solved
Functional benefit
Products and services
- JLS Fund Investment Services Venture capital fund offering accredited investors, family offices, and syndicates access to early-stage investments in neuroscience, psychedelic medicine, and precision neuromedicine companies. The fund finances and helps build portfolio companies developing treatments for neuropsychiatric disorders, age-related diseases, and psychedelic-assisted therapies.
Quantifiable outcome
- Top decile performance claimed for fund returns
Companies that use JLS Fund
Customer profileSegments3 records
Ideal customer profiles3 records
JLS Fund technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
JLS Fund partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered major portfolio exit, portfolio company and industry partner.
- AbbViemajor portfolio exitAbbVie made a billion dollar commitment to Gilgamesh Pharmaceuticals, a JLS Fund portfolio company, representing a significant validation and potential exit event for JLS Fund.
- Entheaportfolio companyEnthea is a mental health company dedicated to providing access to safe and affordable psychedelic-assisted therapy, beginning with ketamine therapy. JLS Fund has invested in this portfolio company.
- ProNovo Therapeuticsportfolio companyProNovo Therapeutics leverages emerging science and cutting-edge technology to develop novel, precision therapeutics to address urgent unmet needs in the treatment of neuropsychiatric disorders such as Major Depressive Disorder and Schizophrenia.
- Psilera Bioscienceportfolio companyPsilera Bioscience reimagines psychoactive natural products as the building blocks for the next generation of neurological products.
- Trippportfolio companyTripp is an award-winning breakthrough wellness platform in the psychedelic space.
- Immunis Biomedicalportfolio companyImmunis is a clinical-stage biotech company developing multi-active biologics with immune modulating factors that can address age-related diseases and immune dysregulation.
- Gilgamesh Pharmaceuticalsportfolio companyGilgamesh is a clinical-stage neuroscience biotech transforming the treatment paradigm of psychiatric diseases. Received a billion dollar commitment from AbbVie in September 2025.
- MAPS (Multidisciplinary Association for Psychedelic Studies)industry partnerJLS team members attend and speak at MAPS conferences and events. MAPS is a non-profit organization conducting clinical trials for MDMA-assisted psychotherapy.
Scale indicators2 records
Recent moves6 records
Expansion highlights5 records
JLS Fund competitors and assessment
Company assessmentBroad incumbents
- Compass Pathways: Public mental-health care company pioneering psilocybin therapy for treatment-resistant depression. Represents the institutional-scale outcome scenario for JLS Fund's portfolio companies.
- ATAI Life Sciences: Public clinical-stage biopharmaceutical platform building and investing in psychedelic mental-health therapies. Overlaps with JLS Fund's Gilgamesh-style thesis at a much larger scale.
Direct peers
- Empath Ventures: Venture fund investing at the intersection of psychedelics, mental health, and consciousness. Comparable AUM scale, target investor base, and thesis overlap with JLS Fund.
- Iter Investments: Specialist investor in psychedelic and plant-medicine companies. Directly comparable mandate and target check size to JLS Fund's portfolio construction.
- Neo Kuma Ventures: Early-stage venture fund focused exclusively on psychedelic medicine and mental health. Direct competitor for the same LP base (family offices, HNW) and many of the same portfolio company opportunities.
- Conscience VC: Early-stage fund targeting psychedelic and consciousness-expanding technologies. Similar stage, sector focus, and LP profile to JLS Fund.
- Noetic Fund: Psychedelic-medicine focused venture fund. Competes directly with JLS Fund for both psychedelic biotech deals and family-office capital.
- Vine Ventures: Multi-stage VC with notable psychedelic and alternative-therapeutics exposure. Operates in overlapping deal flow with JLS Fund in psychedelic biotech rounds.
Emerging players
- MAPS Public Benefit Corporation: Non-profit-affiliated developer of psychedelic-assisted therapies and training. A potential strategic partner and ecosystem player relevant to JLS Fund's thesis.
- Beckley Psytech: Clinical-stage psychedelic medicine company backed by the Beckley Foundation. Both an adjacent investment opportunity and a sector peer signaling the institutional maturation of the space.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
JLS Fund social profiles
Digital presenceJLS Fund financial estimates
Financial estimateRevenue estimate
Valuation estimate
JLS Fund leadership team
Management profileNumber of profiles
Profiles7 records
JLS Fund funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
JLS Fund M&A and investment
M&A and investmentM&A
Investments9 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about JLS Fund
What does JLS Fund do?
JLS Fund is a venture capital fund that finances and helps build companies translating breakthroughs in neuroscience, technology, and data into patient outcomes and value for strategic acquirers. The fund focuses on precision neuromedicine, particularly in the psychedelic medicine sector, deploying capital into early-stage biotech, neuroscience, and digital health companies. Investors gain exposure through management fees on committed capital and carried interest on portfolio exits.
Is JLS Fund a public or private company?
JLS Fund is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was JLS Fund founded?
JLS Fund was founded in 2019. It employs 1 to 10 people.
Where is JLS Fund based?
JLS Fund is headquartered in New York, United States, in the North America region.
How does JLS Fund make money?
One revenue line is on record: venture Capital Fund Management.
Who are JLS Fund's main competitors?
Broad incumbents on record are Compass Pathways and ATAI Life Sciences. Direct peers are Empath Ventures, Iter Investments, Neo Kuma Ventures, Conscience VC, Noetic Fund and Vine Ventures. Emerging players are MAPS Public Benefit Corporation and Beckley Psytech.
Does JLS Fund have an API?
No public API is recorded for JLS Fund.
What industry is JLS Fund in?
JLS Fund's product category is Venture Capital Fund. Its primary akta.pro industry code is FSANAAAB, Early-Stage Venture Capital (Series A/B), with a secondary code of FSANAJAI, Healthcare Access & Life Sciences Impact Funds. Its NAICS code is 523940 and its SIC code is 6282.